692764-07-1

Basic information

• Product Name: 8-BroMo-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester
• Synonyms: 8-BroMo-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester
• CAS NO: 692764-07-1
• Molecular Formula: C12H10BrNO3
• Molecular Weight: 296.1167
• EINECS: -0
• Mol File: 692764-07-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 392.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.555±0.06 g/cm3(Predicted)
• PKA: -0.72±0.70(Predicted)
• CAS DataBase Reference: 8-BroMo-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BroMo-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester(692764-07-1)
• EPA Substance Registry System: 8-BroMo-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester(692764-07-1)

Safety Data

• Hazardous Substances Data: 692764-07-1(Hazardous Substances Data)

Upstream product

• 35975-63-4 2-[(2-bromo-phenylamino)methylene]malonic acid diethyl ester 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 615-36-1 2-bromoaniline 

Downstream Products

• 1314230-86-8 N-(adamantan-1-yl)-4-oxo-8-phenyl-1,4-dihydroquinoline-3-carboxamide 
• 1314230-73-3 N-(adamantan-1-yl)-4-oxo-1-pentyl-8-phenyl-1,4-dihydroquinoline-3-carboxamide 
• 206258-97-1 ethyl 4-chloro-8-bromo-3-quinolinecarboxylate 

Relevant articles and documents

3-(Benzo[: D] thiazol-2-yl)-4-aminoquinoline derivatives as novel scaffold topoisomerase i inhibitor via DNA intercalation: Design, synthesis, and antitumor activities

Twenty-seven 3-(benzo[d]thiazol-2-yl)-4-aminoquinoline derivatives have been designed and synthesized as topoisomerase I inhibitors. The in vitro anti-proliferation evaluation against four human cancer cell lines (MGC-803, HepG-2, T24, and NCI-H460) and one normal cell line (HL-7702) indicated that most of them exhibited potent cytotoxicity. Among them, 5a was identified as the most promising candidate with a low IC50 value of about 2.20 ± 0.14 and was selected for further exploration. Spectroscopic analyses and agarose-gel electrophoresis assays indicated that 5a could interact with DNA and strongly inhibit topoisomerase I (Topo I). Further screening of the Topo I activity of compounds 5b, 5c, 5e, 5f, 5h, 5i, 5j, 5l, and 5n suggested that some of the compounds might exert quite a different cytotoxicity profile to that of 5a. Molecular modeling studies confirmed that 5a adopts a unique mode to interact with DNA and Topo I. Other molecular mechanistic studies suggested that the treatment of MGC-803 cells with 5a induces S phase arrest, up-regulates the pro-apoptotic protein, down-regulates the anti-apoptotic protein, activates caspase-3, and subsequently induces mitochondrial dysfunction so as to induce cell apoptosis. The in vivo efficiency of 5a was also evaluated on MGC-803 xenograft nude mice and the relative tumor growth inhibition was 42.4percent at 12 mg kg-1 without an obvious loss in the body weight. This journal is

Micromolecular reversible BTK inhibitor for treating rheumatoid arthritis

The invention relates to a micromolecular reversible BTK inhibitor for treating rheumatoid arthritis, and specifically provides a compound. The compound is the compound as shown in a formula I, or a stereisomer, a geometrical isomer and a tautomer thereof, nitric oxide, aquo-complex, a solvate, a metabolite and pharmaceutically acceptable salts and prodrugs. The inventor finds that polysubstitutedquinolone compound or derivate thereof as shown in formula I can be used as the BTK inhibitor and is high in activity during treating rheumatoid arthritis.

Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice

Experimental evidence suggests that selective CB2 receptor modulators may provide access to antihyperalgesic agents devoid of psychotropic effects. Taking advantage of previous findings on structure-activity/selectivity relationships for a class of 4-quin